Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | ACACB | O00763 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.37 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.37 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CTSK | P43235 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6298490 | 0.82 | FDPS (0.44) | FDPSALDH1A1SLC6A3TSHRPKM | |
| SCHEMBL4759129 | 0.80 | — | — | |
| SCHEMBL26865302 | 0.79 | HTT (0.45) | FDPSALDH1A1PKMACACB | |
| SCHEMBL3428398 | 0.76 | — | — | |
| SCHEMBL9120605 | 0.76 | — | — | |
| SCHEMBL5226040 | 0.76 | FDPS (0.43) | FDPSALDH1A1TSHRPKMCYP3A4 | |
| SCHEMBL5043060 | 0.76 | FDPS (0.43) | FDPSALDH1A1SLC6A3TSHRPKM | |
| SCHEMBL19765222 | 0.75 | CYP3A4 (0.46) | FDPSALDH1A1PKMACACBCYP3A4 | |
| SCHEMBL15572413 | 0.75 | FDPS (0.46) | FDPSALDH1A1SLC6A3TSHRPKM | |
| SCHEMBL15573121 | 0.75 | FDPS (0.46) | FDPSALDH1A1SLC6A3TSHRPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11672800-B2 | Combination therapies with EHMT2 inhibitors | Epizyme, Inc. (US) | 2023-06-13 | — | — | US | disclosed |
| US-9440938-B2 | Sulfonamide derivative having PGD2 receptor antagonistic activity | SHIONOGI & CO., LTD. (JP) | 2016-09-13 | — | — | US | disclosed |
| US-20150158833-A1 | SULFONAMIDE DERIVATIVE HAVING PGD2 RECEPTOR ANTAGONISTIC ACTIVITY | SHIONOGI & CO (JP) | 2015-06-11 | — | — | US | disclosed |
| US-20100298270-A1 | Novel Compounds and Methods of Using Them | SYNDAX PHARMACEUTICALS, INC. (US) | 2010-11-25 | — | — | US | disclosed |
| US-7449447-B2 | Peptidomimetic NS3-serine protease inhibitors of hepatitis C virus | SCHERING CORPORATION (US) | 2008-11-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150158833-A1 | SULFONAMIDE DERIVATIVE HAVING PGD2 RECEPTOR ANTAGONISTIC ACTIVITY | PTGDR, PTGDR2, CNR2 | FDPS 4182/4885ALDH1A1 1440/4885SLC6A3 3310/4885 |
| US-20100298270-A1 | Novel Compounds and Methods of Using Them | HDAC1, HDAC3, HDAC6 | FDPS 2762/4885ALDH1A1 374/4885SLC6A3 4273/4885 |
| US-11672800-B2 | Combination therapies with EHMT2 inhibitors | EHMT2, BHMT, SHMT2 | FDPS 2043/4885ALDH1A1 430/4885SLC6A3 2300/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.